Rising Prevalence of Hemophilia, Increasing Adoption of Recombinant Therapies, and Breakthroughs in Gene Therapy Propel Market Growth.Pune, March 12, 2025 (GLOBE NEWSWIRE) -- Hemophilia Market Size & ...

“Gene therapy for hemophilia A with the use of lentiviral vector-transduced autologous HSCs resulted in stable factor VIII ...

Market Valuation Set to Surge from USD 13.23 Billion in 2024 at a CAGR of 5.69% ...

People with hemophilia A bleed and bruise easily, and their blood takes a long time to form clots. Hemophilia A is a rare, serious condition that has no cure, but is treatable. Hemophilia A is ...

Weak demand for Pfizer’s hemophilia gene therapy Beqvez has led the pharmaceutical company to “cease further development and commercialization” of the one-time treatment, a Pfizer spokesperson ...

Feb 20 (Reuters) - Pfizer (PFE.N), opens new tab said on Thursday it will stop global development and commercialization of its hemophilia gene therapy, Beqvez, citing soft demand from patients and ...

The changes at Spark follow Roche's decision last year to halt development of a gene therapy for hemophilia A that was the ...

Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. The New York pharma is ending global development and commercialization of ...

When a test determined that Walter had hemophilia, his Omaha owner joined a group seeking to raise $50,000 for a clinical trial of a gene therapy for dogs. Emily Wiley wasn’t looking to take ...

Jammu Hemophilia Society, in collaboration with the Department of Paediatrics of Shri Maharaja Gulab Singh (SMGS) Hospital ...

Approved in 2022 by the FDA, Hemgenix is the first gene therapy for the treatment of adults with hemophilia B who currently use factor IX prophylaxis therapy, have current or historical life ...